Molecular review explores Siglec signaling pathways in cancer and inflammatory disorders

Photo by Ayanda Kunene / Unsplash

Frontiers in Medicine Published May 21, 2026 Medically reviewed May 21, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider targeting the Siglec glycan axis as a promising therapeutic opportunity for various conditions.

This publication is a molecular review focusing on the human Siglecs family of molecules. The scope of the article encompasses a broad range of conditions, including cancer, autoimmune disorders, inflammatory disorders, neurodegeneration, and infections. The authors synthesize current understanding of Siglec signaling pathways, specifically distinguishing between ITIM dependent inhibitory mechanisms and ITAM/DAP12-associated activation.

The review does not report a specific sample size or follow-up duration. Consequently, no primary or secondary outcomes, adverse events, or serious adverse events are detailed in this source. The text does not provide specific numerical data regarding efficacy or safety profiles.

The authors conclude that targeting the Siglec glycan axis offers promising therapeutic opportunities. However, because this is a review and not a primary trial, the findings represent a synthesis of existing knowledge rather than new clinical evidence. The practice relevance is framed cautiously to reflect the current state of molecular understanding.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Siglecs are sialic acid-binding immunoglobulin-like receptors that regulate immune responses through inhibitory and activating signaling pathways. By recognizing sialoglycan ligands, they modulate innate and adaptive immunity, and their dysregulation is increasingly linked to diverse human diseases. This review highlights the roles of human Siglecs in disease pathogenesis, including cancer, autoimmune and inflammatory disorders, neurodegeneration, and infections. We summarize key regulatory mechanisms such as transcription factors, microRNAs, and protein interactions and outline major signaling pathways underlying Siglec-mediated immune modulation. At the molecular level, Siglecs signal via ITIM dependent inhibitory pathways SHP-1/SHP-2 or ITAM/DAP12-associated activation SYK/MAPK, maintaining immune homeostasis. Targeting the Siglec glycan axis offers promising therapeutic opportunities.